hepatitis inflammation liver people animals hepatitis symptoms whereas others develop yellow discoloration skin whites eyes jaundice poor appetite vomiting tiredness abdominal pain hepatitis acute resolves within six months chronic lasts longer six acute hepatitis resolve progress chronic hepatitis rarely result acute liver chronic hepatitis may progress scarring liver cirrhosis liver failure liver hepatitis commonly caused virus hepatovirus b c viruses also cause liver inflammation including cytomegalovirus virus yellow fever virus common causes hepatitis include heavy alcohol use certain medications toxins infections autoimmune nonalcoholic steatohepatitis hepatitis e mainly spread contaminated food hepatitis b mainly sexually transmitted may also passed mother baby pregnancy childbirth spread infected hepatitis c commonly spread infected blood may occur needle sharing intravenous drug hepatitis infect people already infected hepatitis hepatitis b preventable medications may used treat chronic viral antiviral medications recommended chronic hepatitis c except conditions limit life specific treatment nash physical activity healthy diet weight loss autoimmune hepatitis may treated medications suppress immune liver transplant may option acute chronic liver worldwide hepatitis occurred million people chronic hepatitis b affected million people chronic hepatitis c million united states nash affects million people alcoholic hepatitis affects million hepatitis results million deaths year occur indirectly liver scarring liver united states hepatitis estimated occur people year results word derived greek hêpar ἧπαρ meaning liver itis ῖτις meaning hepatitis broad spectrum presentations range complete lack symptoms severe liver acute form hepatitis generally caused viral infection characterized constitutional symptoms typically chronic hepatitis presents similarly manifest signs symptoms specific liver dysfunction longstanding inflammation damage acute viral hepatitis follows three distinct phases druginduced hepatitis autoimmune hepatitis present similarly acute viral hepatitis slight variations symptoms depending cases druginduced hepatitis manifest systemic signs allergic reaction including rash fever serositis inflammation membranes lining certain organs elevated eosinophils type white blood cell suppression bone marrow fulminant hepatitis massive hepatic cell death rare lifethreatening complication acute hepatitis occur cases hepatitis b e addition druginduced autoimmune complication frequently occurs instances hepatitis b coinfection rate pregnant women hepatitis e rate addition signs acute hepatitis people also demonstrate signs coagulopathy abnormal coagulation studies easy bruising bleeding encephalopathy confusion disorientation mortality due fulminant hepatitis typically result various complications including cerebral edema gastrointestinal bleeding sepsis respiratory failure kidney acute cases hepatitis seen resolved well within sixmonth period hepatitis continued six months termed chronic chronic hepatitis often asymptomatic early course detected liver laboratory studies screening purposes evaluate nonspecific inflammation progresses patients develop constitutional symptoms similar acute hepatitis including fatigue nausea vomiting poor appetite joint jaundice occur well much later disease process typically sign advanced chronic hepatitis interferes hormonal functions liver result acne hirsutism abnormal hair growth amenorrhea lack menstrual period extensive damage scarring liver time defines cirrhosis condition livers ability function permanently results jaundice weight loss coagulopathy ascites abdominal fluid collection peripheral edema leg cirrhosis lead lifethreatening complications hepatic encephalopathy esophageal varices hepatorenal syndrome liver causes hepatitis divided following major categories infectious metabolic ischemic autoimmune genetic infectious agents include viruses bacteria parasites metabolic causes include prescription medications toxins notably alcohol nonalcoholic fatty liver disease autoimmune genetic causes hepatitis involve genetic predispositions tend affect characteristic populationscitation needed viral hepatitis common type hepatitis worldwide especially asia viral hepatitis caused five different viruses hepatitis b c hepatitis hepatitis e behave similarly transmitted route common developing countries selflimiting illnesses lead chronic hepatitis b hepatitis c hepatitis transmitted blood mucous membranes exposed infected blood body fluids semen vaginal viral particles also found saliva breastmilk kissing sharing utensils breastfeeding lead transmission unless fluids introduced open sores many families safe drinking water live unhygienic homes contracted hepatitis saliva blood droplets often carried water bloodborne illnesses spread quickly unsanitary hepatitis b c present either acutely hepatitis defective virus requires hepatitis b replicate found hepatitis b adults hepatitis b infection commonly selflimiting less progressing chronic state chronically infected developing cirrhosis liver infection infants children frequently leads chronic unlike hepatitis b cases hepatitis c lead chronic hepatitis c second common cause cirrhosis us second alcoholic blood transfusions major factor spreading hepatitis c since widespread screening blood products hepatitis c began risk acquiring hepatitis c blood transfusion decreased approximately million parasites also infect liver activate immune response resulting symptoms acute hepatitis increased serum ige though chronic hepatitis possible chronic protozoans trypanosoma cruzi leishmania species malariacausing plasmodium species cause liver another protozoan entamoeba histolytica causes hepatitis distinct liver worms cestode echinococcus granulosus also known dog tapeworm infects liver forms characteristic hepatic hydatid liver flukes fasciola hepatica clonorchis sinensis live bile ducts cause progressive hepatitis liver bacterial infection liver commonly results pyogenic liver abscesses acute hepatitis granulomatous chronic liver pyogenic abscesses commonly involve enteric bacteria escherichia coli klebsiella pneumoniae composed multiple bacteria acute hepatitis caused neisseria meningitidis neisseria gonorrhoeae bartonella henselae borrelia burgdorferi salmonella species brucella species campylobacter chronic granulomatous hepatitis seen infection mycobacteria species tropheryma whipplei treponema pallidum coxiella burnetii rickettsia excessive alcohol consumption significant cause hepatitis common cause cirrhosis alcoholic hepatitis within spectrum alcoholic liver disease ranges order severity reversibility alcoholic steatosis least severe reversible alcoholic hepatitis cirrhosis liver cancer severe least hepatitis usually develops yearslong exposure alcohol occurring important risk factors development alcoholic hepatitis quantity duration alcohol longterm alcohol intake excess grams alcohol day men grams day women associated development alcoholic hepatitis beer ounces wine equivalent alcoholic hepatitis vary asymptomatic hepatomegaly enlarged liver symptoms acute chronic hepatitis liver many chemical agents including medications industrial toxins herbal dietary supplements cause spectrum druginduced liver injury varies acute hepatitis chronic hepatitis acute liver toxins medications cause liver injury variety mechanisms including direct cell damage disruption cell metabolism causing structural drugs paracetamol exhibit predictable dosedependent liver damage others isoniazid cause idiosyncratic unpredictable reactions vary wide variations mechanisms liver injury latency period exposure development clinical many types drugs cause liver injury including analgesic paracetamol antibiotics isoniazid nitrofurantoin amoxicillinclavulanate erythromycin trimethoprimsulfamethoxazole anticonvulsants valproate phenytoin cholesterollowering statins steroids oral contraceptives anabolic steroids highly active antiretroviral therapy used treatment amoxicillinclavulanate common cause druginduced liver injury paracetamol toxicity common cause acute liver failure united states herbal remedies dietary supplements another important cause hepatitis common causes druginduced hepatitis unitedstatesbased drug induced liver injury network linked cases hepatotoxicity herbal dietary united states herbal dietary supplements unlike pharmaceutical drugs unregulated food drug national institutes health maintains livertox archived wayback machine database consumers track known prescription nonprescription compounds associated liver exposure hepatotoxins occur accidentally intentionally ingestion inhalation skin absorption industrial toxin carbon tetrachloride wild mushroom amanita phalloides known nonalcoholic hepatitis within spectrum nonalcoholic liver disease nald ranges severity reversibility nonalcoholic fatty liver disease nafld nonalcoholic steatohepatitis nash cirrhosis liver cancer similar spectrum alcoholic liver nonalcoholic liver disease occurs people little history alcohol use instead strongly associated metabolic syndrome obesity insulin resistance diabetes time nonalcoholic fatty liver disease progress nonalcoholic steatohepatitis additionally involves liver cell death liver inflammation possible factors accelerating progression nafld nash obesity older age nonafrican american ethnicity female gender diabetes mellitus hypertension higher alt ast level higher astalt ratio low platelet count ultrasound steatosis early stages nafld early nash patients asymptomatic mild right upper quadrant pain diagnosis suspected basis abnormal liver function disease progresses symptoms typical chronic hepatitis may imaging show fatty liver liver biopsy demonstrate inflammation fibrosis characteristic patients nash develop nash recognized third common cause liver disease united autoimmune hepatitis chronic disease caused abnormal immune response liver disease thought genetic predisposition associated certain human leukocyte antigens involved immune autoimmune diseases circulating autoantibodies may present helpful autoantibodies found patients autoimmune hepatitis include sensitive less specific antinuclear antibody ana smooth muscle antibody sma atypical perinuclear antineutrophil cytoplasmic antibody autoantibodies less common specific autoimmune hepatitis antibodies liver kidney microsome soluble liver antigen autoimmune hepatitis also triggered drugs nitrofurantoin hydralazine methyldopa liver transplant viruses hepatitis epsteinbarr virus autoimmune hepatitis present anywhere within spectrum asymptomatic acute chronic hepatitis fulminant liver patients asymptomatic time diagnosis suspected basis abnormal liver function studies show cases present signs symptoms acute autoimmune diseases autoimmune hepatitis usually affects young females though affect patients either sex age patients exhibit classic signs symptoms autoimmunity fatigue anemia anorexia amenorrhea acne arthritis pleurisy thyroiditis ulcerative colitis nephritis maculopapular autoimmune hepatitis increases risk cirrhosis risk liver cancer increased year many people autoimmune hepatitis autoimmune autoimmune hepatitis distinct autoimmune diseases liver primary biliary cirrhosis primary sclerosing cholangitis also lead scarring fibrosis cirrhosis genetic causes hepatitis include deficiency hemochromatosis wilsons deficiency codominant mutation gene results abnormal accumulation mutant aat protein within liver cells leading liver hemochromatosis wilsons disease autosomal recessive diseases involving abnormal storage hemochromatosis excess amounts iron accumulate multiple body sites including liver lead wilsons disease excess amounts copper accumulate liver brain causing cirrhosis liver involved deficiency wilsons disease tend present hepatitis neonatal period hemochromatosis typically presents adulthood onset clinical disease usually age ischemic hepatitis also known shock liver results reduced blood flow liver shock heart failure vascular condition often associated heart failure also caused shock sepsis blood testing person ischemic hepatitis show high levels transaminase enzymes ast alt condition usually resolves underlying cause treated successfully ischemic hepatitis rarely causes permanent liver hepatitis also occur neonates attributable variety causes typically seen congenital perinatal infection hepatitis viruses toxoplasma rubella cytomegalovirus syphilis cause neonatal structural abnormalities biliary atresia choledochal cysts lead cholestatic liver injury leading neonatal metabolic diseases glycogen storage disorders lysosomal storage disorders also neonatal hepatitis idiopathic cases biopsy often shows large multinucleated cells liver disease termed giant cell hepatitis may associated viral infection autoimmune disorders drug specific mechanism varies depends underlying cause hepatitis generally initial insult causes liver injury activation inflammatory response become chronic leading progressive fibrosis pathway hepatic viruses cause viral hepatitis best understood case hepatitis b viruses directly activate apoptosis cell rather infection liver cells activates innate adaptive arms immune system leading inflammatory response causes cellular damage death including viralinduced apoptosis via induction death receptormediated signaling depending strength immune response types immune cells involved ability virus evade bodys defense infection either lead clearance acute disease persistence chronic disease chronic presence virus within liver cells results multiple waves inflammation injury wound healing time lead scarring fibrosis culminate hepatocellular people impaired immune response greater risk developing chronic natural killer cells primary drivers initial innate response create cytokine environment results recruitment thelper cytotoxic type interferons cytokines drive antiviral chronic hepatitis b c natural killer cell function steatohepatitis seen alcoholic nonalcoholic liver disease culmination cascade events began injury case nonalcoholic steatohepatitis cascade initiated changes metabolism associated obesity insulin resistance lipid alcoholic hepatitis chronic excess alcohol use though inciting event may differ progression events similar begins accumulation free fatty acids ffa breakdown products liver cells process called initially reversible process overwhelms hepatocytes ability maintain lipid homeostasis leading toxic effect fat molecules accumulate broken setting oxidative stress time abnormal lipid deposition triggers immune system via tolllike receptor resulting production inflammatory cytokines tnf cause liver cell injury events mark transition steatohepatitis setting chronic injury fibrosis eventually develops setting events lead cirrhosis hepatocellular microscopically changes seen include steatosis large swollen hepatocytes ballooning evidence cellular injury cell death apoptosis necrosis evidence inflammation particular zone liver variable degrees fibrosis mallory diagnosis hepatitis made basis following persons signs symptoms medical history including sexual substance use history blood tests imaging liver general viral hepatitis acute causes hepatitis persons blood tests clinical picture sufficient causes hepatitis especially chronic causes blood tests may case liver biopsy gold standard establishing diagnosis histopathologic analysis able reveal precise extent pattern inflammation biopsy typically initial diagnostic test invasive associated small significant risk bleeding increased people liver injury blood testing includes liver enzymes serology ie autoantibodies nucleic acid testing ie hepatitis virus dnarna blood chemistry complete blood characteristic patterns liver enzyme abnormalities point certain causes stages generally ast alt elevated cases hepatitis regardless whether person shows degree elevation ie levels hundreds vs thousands predominance ast vs alt elevation ratio ast alt informative ultrasound ct mri identify steatosis fatty changes liver tissue nodularity liver surface suggestive ct especially mri able provide higher level detail allowing visualization characterize structures vessels tumors within unlike steatosis cirrhosis imaging test able detect liver inflammation ie hepatitis liver biopsy definitive diagnostic test able assess inflammation fibrosis viral hepatitis primarily diagnosed blood tests levels viral antigens hepatitis b surface core antigen antiviral antibodies antihepatitis b surface antibody antihepatitis antibody viral early infection ie within week igm antibodies found late infection recovery igg antibodies present remain body therefore patient positive igg antibody negative igm antibody considered immune virus via either prior infection recovery prior case hepatitis b blood tests exist multiple virus antigens different components virion particle combination antigen antibody positivity provide information stage infection acute chronic degree viral replication infectivity apparent distinguishing factor alcoholic steatohepatitis ash nonalcoholic steatohepatitis nash history excessive alcohol thus patients negligible alcohol use diagnosis unlikely alcoholic hepatitis drink alcohol diagnosis may likely alcoholic nonalcoholic hepatitis especially concurrent obesity diabetes metabolic syndrome case alcoholic nonalcoholic hepatitis distinguished pattern liver enzyme abnormalities specifically alcoholic steatohepatitis astalt ratio nonalcoholic steatohepatitis altast ratio liver biopsies show identical findings patients ash nash specifically presence polymorphonuclear infiltration hepatocyte necrosis apoptosis form ballooning degeneration mallory bodies fibrosis around veins purpose screening viral hepatitis identify people infected disease early possible even symptoms transaminase elevations may present allows early treatment prevent disease progression decrease likelihood transmission hepatitis causes acute illness progress chronic liver disease therefore role screening assess immune status people high risk contracting virus well people known liver disease hepatitis infection could lead liver people groups already immune receive hepatitis vaccinecitation needed high risk need screening presence antihepatitis igg blood indicates past infection virus prior cdc uspstf acog recommend routine hepatitis b screening certain highrisk specifically populations include people screening consists blood test detects hepatitis b surface antigen hbsag hbsag present second test usually done blood sample detects antibody hepatitis b core antigen antihbcag differentiate acute chronic people highrisk whose blood tests negative hbsag receive hepatitis b vaccine prevent future cdc uspstf aasld acog recommend screening people high risk hepatitis c populations include people people groups whose exposure ongoing screening periodic though set optimal screening aasld recommends screening men sex men hivpositive people born us screened unless exposure screening consists blood test detects antihepatitis c virus antibody antihepatitis c virus antibody present confirmatory test detect hcv rna indicates chronic cdc uspstf aasld acog recommend screening people high risk hepatitis populations include people hepatitis extremely rare symptoms include chronic diarrhea anal intestinal blisters purple urine burnt popcorn scented screening consists blood test detects antihepitits virus antibbody antihepitits virus antibody present confirmatory test detect hdv rna dna inidicates chronic cdc recommends hepatitis vaccine children beginning age one well previously immunized high risk contracting children months age older vaccination given shot muscle two doses months apart started age dosing slightly different adults depending type vaccine vaccine hepatitis two doses given months apart depending vaccine combined hepatitis hepatitis b doses may cdc recommends routine vaccination children age hepatitis b also recommend desire high routine vaccination hepatitis b starts first dose administered shot muscle newborn discharged hospital additional two doses administered child babies born mother hepatitis b surface antigen positivity first dose unique addition vaccine hepatitis immune globulin also administered within hours birth newborns also regularly tested infection least first year also combination formulation includes hepatitis b currently vaccines available united states hepatitis c group china published article regarding development vaccine hepatitis march united states government process recruiting participants phase iv trial hepatitis e hepatitis transmitted primarily oralfecal route mainstay prevention aside vaccination good hygiene access clean water proper handling hepatitis b c transmitted blood multiple bodily fluids prevention aimed screening blood prior transfusion abstaining use injection drugs safe needle sharps practices healthcare settings safe sex hepatitis virus requires person first infected hepatitis b virus prevention efforts focus limiting spread hepatitis b people chronic hepatitis b infection risk superinfection hepatitis virus preventive strategies hepatitis hepatitis e spread primarily oralfecal route may also spread blood mother fetus mainstay hepatitis e prevention similar hepatitis namely good hygiene clean water excessive alcohol consumption lead hepatitis cirrhosis following maximal recommendations alcohol prevent mafld recommended maintain normal weight eat healthy diet avoid added sugar exercise united states universal immunization led twothirds decrease hospital admissions medical expenses due hepatitis united states new cases hepatitis b decreased group saw greatest decrease children adolescents likely reflecting implementation hepatitis c infections year declining since began increase data unclear whether decline attributed needle exchange people alcoholic hepatitis may symptoms difficult diagnose number people disease probably higher many programs alcoholics anonymous successful decreasing death due cirrhosis difficult evaluate success decreasing incidence alcoholic treatment hepatitis varies according type whether acute chronic severity disease hepatitis usually progress chronic state rarely requires treatment supportive includes measures providing intravenous iv hydration maintaining adequate rarely people hepatitis virus rapidly develop liver failure termed fulminant hepatic failure especially elderly preexisting liver disease especially hepatitis mortality risk factors include greater age chronic hepatitis cases aggressive supportive therapy liver transplant may healthy patients recover longlasting effects antiviral treatment age comorbid conditions result prolonged severe illness certain patients warrant hospitalization especially present clinical signs ascites peripheral edema hepatic encephalopathy laboratory signs hypoglycemia prolonged prothrombin time low serum albumin high serum rare severe acute cases patients successfully treated antiviral therapy similar used cases chronic hepatitis b nucleoside analogues entecavir tenofovir dearth clinical trial data drugs used treat prone developing resistance experts recommend reserving treatment severe acute cases mild chronic hepatitis b management aims control viral replication correlated progression seven drugs approved united firstline treatments currently used include peg ifn entecavir tenofovir subject patient physician treatment initiation guided recommendations issued american association study liver diseases aasld european association study liver easl based detectable viral levels hbeag positive negative status alt levels certain cases family history hcc liver patients compensated cirrhosis treatment recommended regardless hbeag status alt level recommendations differ regarding hbv dna levels aasld recommends treating dna levels detectable iuml easl recommend treating hbv dna levels detectable patients decompensated cirrhosis treatment evaluation liver transplantation recommended cases hbv dna currently multidrug treatment recommended treatment chronic hbv effective long term individual treatment entecavir american association study liver diseases infectious diseases society america aasldidsa recommend antiviral treatment patients chronic hepatitis c infection except additional chronic medical conditions limit life acquired persistence hepatitis c virus rule resulting chronic hepatitis c goal treatment prevention hepatocellular carcinoma best way reduce longterm risk hcc achieve sustained virological response svr defined undetectable viral load weeks treatment completion indicates currently available treatments include indirect direct acting antiviral indirect acting antivirals include pegylated interferon peg ifn ribavirin rbv combination historically basis therapy duration response treatments varies based agents poorly tolerated still used resourcepoor highresource countries supplanted direct acting antiviral agents first appeared agents target proteins responsible viral replication include following three drugs used various combinations sometimes combined ribavirin based patients genotype delineated genotypes genotype prevalent genotype united states around world cured direct acting antiviral firstline therapy combination sofosbuvir ledipasvir sofldv weeks patients including advanced fibrosis certain patients early disease need weeks treatment advanced fibrosis cirrhosis responded prior treatment require cost remains major factor limiting access drugs particularly lowresource nations cost regimen sofldv estimated hepatitis difficult treat effective treatments lacking interferon alpha proven effective inhibiting viral activity temporary similar hepatitis treatment hepatitis e supportive includes rest ensuring adequate nutrition hospitalization may required particularly severe cases pregnant firstline treatment alcoholic hepatitis treatment abstain completely alcohol reversal liver disease longer life possible patients every disease stage shown benefit prevention additional liver addition referral psychotherapy treatment programs treatment include nutritional psychosocial evaluation patients also treated appropriately related signs symptoms ascites hepatic encephalopathy severe alcoholic hepatitis poor prognosis notoriously difficult without treatment patients may die within month evidence shows treatment may extend life beyond one month ie reduce shortterm available treatment options include pentoxifylline ptx nonspecific tnf inhibitor corticosteroids prednisone prednisolone cs corticosteroids nacetylcysteine cs nac corticosteroids pentoxifylline cs data suggest cs alone cs nac effective reducing shortterm unfortunately corticosteroids contraindicated patients active gastrointestinal bleeding infection kidney failure cases ptx may considered casebycase basis lieu cs evidence shows ptx better treatment may comparable cs data show evidence benefit unfortunately currently drug treatments decrease patients risk dying longer term months weak evidence suggests milk thistle extracts may improve survival alcoholic liver disease improve certain liver tests serum bilirubin ggt without causing side effects firm recommendation made milk thistle without modified maddreys discriminant function may used evaluate severity prognosis alcoholic hepatitis evaluates efficacy using alcoholic hepatitis corticosteroid treatment main treatment nash gradual weight loss increased physical activity united states medications approved treat autoimmune hepatitis commonly treated immunosuppressants corticosteroids prednisone prednisolone active version prednisolone require liver synthesis either alone combination azathioprine suggested combination therapy preferred allow lower doses corticosteroids reduce associated side although result treatment efficacy treatment autoimmune hepatitis consists two phases initial maintenance phase initial phase consists higher doses corticosteroids tapered number weeks lower dose used combination azathioprine given initial phase well initial phase completed maintenance phase consists lower dose corticosteroids combination therapy azathioprine liver blood markers normalized treatment results patients achieving normal liver test values two years average nearly patients hepatitis infections recover completely without complications healthy prior infection similarly acute hepatitis b infections favorable course towards complete recovery certain factors may portend poorer outcome comorbid medical conditions initial presenting symptoms ascites edema overall mortality rate acute hepatitis low total cases hepatitis b rates higher certain populations super infection hepatitis b pregnant women contrast hepatitis b hepatitis c carries much higher risk progressing chronic hepatitis approaching cirrhosis reported develop patients chronic hepatitis ccitation needed rare complications acute hepatitis include pancreatitis aplastic anemia peripheral neuropathy despite relatively benign course viral cases hepatitis fulminant hepatitis represents rare feared complication fulminant hepatitis commonly occurs hepatitis b e cases hepatitis e lead fulminant hepatitis pregnant women particularly susceptible occurring mortality rates cases fulminant hepatitis rise patients survive often make complete recovery liver transplantation lifesaving patients fulminant liver hepatitis infections transform benign cases hepatitis b severe progressive hepatitis phenomenon known acute hepatitis b infections become less likely progress chronic forms age patient increases rates progression approaching vertically transmitted cases infants compared risk young overall fiveyear survival rate chronic hepatitis b ranges mild cases severe cases patients acquire hepatitis time hepatitis b coinfection recover without developing chronic infection people hepatitis b later acquire hepatitis superinfection chronic infection much common liver disease progression chronic hepatitis c progresses towards cirrhosis estimates cirrhosis prevalence years major causes mortality hepatitis c end stage liver disease hepatocellular carcinoma important additional long term complication cause death chronic hepatitis rates mortality increase progression underlying liver disease series patients compensated cirrhosis due hcv shown survival rates survival rate drops upon cirrhosis becomes decompensated hepatitis found throughout world manifests large outbreaks epidemics associated fecal contamination water food hepatitis viral infection predominant children ages rare infection infected children little apparent clinical illness contrast adults greater symptomatic infection rates highest low resource countries inadequate public sanitation large concentrated regions much children younger years old infected immune corresponding lower rates clinically symptomatic disease availability childhood vaccine significantly reduced infections united states incidence declining paradoxically highest rates new infection occur young adults adults present worse clinical specific populations greatest risk include travelers endemic regions men sex men occupational exposure nonhuman primates people clotting disorders received clotting factors people history chronic liver disease coinfection hepatitis lead fulminant hepatitis intravenous drug users hepatitis b common cause viral hepatitis world million chronic carriers virus million united approximately twothirds patients develop acute hepatitis b infection identifiable exposure acutely infected become lifetime carriers risk infection highest among intravenous drug users people highrisk sexual behaviors healthcare workers people multiple transfusions organ transplant patients dialysis patients newborns infected birthing close deaths world attributed hepatitis endemic regions subsaharan africa east asia many adults chronic carrier rates developed nations significantly lower encompassing less endemic regions transmission thought associated exposure birth close contact young chronic hepatitis c major cause liver cirrhosis hepatocellular common medical reason liver transplantation due severe estimated million people world affected disease representing little world developing regions africa asia south america prevalence high egypt rates hepatitis c infection high documented associated iatrogenic contamination related schistosomiasis treatment currently united states approximately million adults estimated hepatitis c particularly prevalent among people born group people prevalence high versus general us chronic carriers hepatitis c unaware infection common mode transmission hepatitis c virus exposure blood products via blood transfusions prior intravenous drug history intravenous drug injection important risk factor chronic hepatitis susceptible populations include engaged highrisk sexual behavior infants infected mothers healthcare hepatitis virus causes chronic fulminant hepatitis context coinfection hepatitis b primarily transmitted via nonsexual contact via susceptibility hepatitis differs geographic united states northern europe populations risk intravenous drug users people receive multiple mediterranean hepatitis predominant among hepatitis b virus coinfected similar hepatitis hepatitis e manifests large outbreaks epidemics associated fecal contamination water accounts deaths annually approximately million people worldwide thought infected affects predominantly young adults causing acute infected pregnant women hepatitis e infection lead fulminant hepatitis third trimester mortality rates high weakened immune systems organ transplant recipients also infection rare united states rates high developing world africa asia central america middle many genotypes exist differentially distributed around evidence hepatitis e infection animals serving reservoir human alcoholic hepatitis ah severe form onemonth mortality high people develop ah men women higher risk developing ah complications likely secondary high body fat differences alcohol contributing factors include younger age binge pattern drinking poor nutritional status obesity hepatitis c estimated much people ah also infected hepatitis population presence hepatitis c virus leads severe disease faster progression cirrhosis hepatocellular carcinoma increased obesity increases likelihood progression cirrhosis cases alcoholic estimated people ah progress nonalcoholic steatohepatitis nash projected become top reason liver transplantation united states supplanting chronic liver disease due hepatitis us population nafld estimated prevalence nash world nash patients develop cirrhosis per year likely progress hepatocellular worldwide estimated prevalence hepatocellular carcinoma related nafld nash thought primary cause cirrhosis approximately patients united states representing general initial accounts syndrome think likely hepatitis begin occur around bc clay tablets served medical handbooks ancient sumerians described first observations jaundice sumerians believed liver home soul attributed findings jaundice attack liver devil named around bc hippocrates recorded first documentation epidemic jaundice particular noting uniquely fulminant course cohort patients died within two weeks wrote bile contained liver full phlegm blood eruptsafter eruption patient soon raves becomes angry talks nonsense barks like given poor sanitary conditions war infectious jaundice played large role major cause mortality among troops napoleonic wars american revolutionary war world world war ii estimates soldiers affected hepatitis upwards million world war ii soldiers received vaccines diseases yellow fever vaccines stabilized human serum presumably contaminated hepatitis viruses often created epidemics suspected epidemics due separate infectious agent due yellow fever virus noting cases jaundice months vaccination total patients vaccinated changing seed virus strain cases jaundice observed subsequent new york university researcher named saul krugman continued research infamously experiments mentally disabled children willowbrook state school new york crowded urban facility hepatitis infections highly endemic student body krugman injected students gamma globulin type antibody observing temporary protection infection antibody provided tried injected live hepatitis virus students krugman also controversially took feces infected students blended milkshakes fed newly admitted research received much controversy people protested questionable ethics surrounding chosen target population henry beecher one foremost critics article new england journal medicine arguing parents unaware risks consent research done benefit others expense moreover argued poor families mentally disabled children often felt pressured join research project gain admission school educational support resources would come along others medical community spoke support krugmans research terms widespread benefits understanding hepatitis virus willowbrook continues commonly cited example debates medical next insight regarding hepatitis b serendipitous one dr baruch blumberg researcher nih set research hepatitis rather studied lipoprotein genetics travelled across globe collecting blood samples investigating interplay disease environment genetics goal designing targeted interventions atrisk people could prevent getting noticed unexpected interaction blood patient hemophilia received multiple transfusions protein found blood indigenous australian named protein australia antigen made focus research found higher prevalence protein blood patients developing countries compared developed ones noted associations antigen diseases like leukemia eventually came unifying conclusion australia antigen associated viral hepatitis david dane first isolated hepatitis b virion londons middlesex hospital named virion dane based association surface hepatitis b virus australia antigen renamed hepatitis b surface antigen hbsag blumberg continued study antigen eventually developed first hepatitis b vaccine using plasma rich hbsag received nobel prize medicine overall hepatitis accounts significant portion healthcare expenditures developing developed nations expected rise several developing hepatitis infections selflimited events associated significant costs united estimated direct indirect costs approximately respectively per case average work days lost per infected report demonstrated single hospitalization related hepatitis cost average resulted around million total annual healthcare cost effectiveness studies found widespread vaccination adults feasible stated combination hepatitis b vaccination children risk groups people endemic areas healthcare workers may hepatitis b accounts much larger percentage health care spending endemic regions like accounted south koreas total health care expenditures resulted million direct large majority sum spent treating disease symptoms chronic hepatitis b infections endemic united states accounted million hospitalization costs year number grew billion remained stable may attributable introduction effective drug therapies vaccination people infected chronic hepatitis c tend frequent users health care system estimated person infected hepatitis c united states result monthly cost number nearly doubles people compensated stable cirrhosis monthly cost people decompensated worsening cirrhosis almost five times large wideranging effects hepatitis make difficult estimate indirect costs studies speculated total cost billion annually united canada hcv related costs attributable cirrhosis total expenditures related virus expected peak million year largest outbreak hepatitis virus united states history occurred among people ate nowdefunct mexican food restaurant located monaca pennsylvania late people visited restaurant september october infected virus three died direct outbreak brought attention health officials local emergency medicine physicians noticed significant increase cases hepatitis conducting investigation cdc attributed source outbreak use contaminated raw green onion restaurant purchasing green onion stock farms mexico believed green onions may contaminated use contaminated water crop irrigation rinsing icing handling vegetables infected green onion caused similar outbreaks hepatitis southern united states prior cdc believes restaurants use large communal bucket chopped raw green onion allowed noncontaminated plants mixed contaminated ones increasing number vectors infection amplifying restaurant closed discovered source people given hepatitis immune globulin either eaten restaurant close contact someone persons infected hiv particularly high burden hivhcv recent study likelihood infected hepatitis c virus six times greater also prevalence hivhcv coinfection worldwide estimated representing million intravenous drug use independent risk factor hcv study prevalence hivhcv coinfection markedly higher injected drugs compared general population study hivhcv coinfection among hiv positive men sex men msm overall prevalence antihepatitis c antibodies estimated increased among hiv positive msm also injected vertical transmission significant contributor new hbv cases year transmission mother neonate endemic vertical transmission occurs largely via neonates exposure maternal blood vaginal secretions risk progression chronic infection approximately among adults contract virus high among neonates subject vertical risk viral transmission approximately maternal blood positive hbsag also positive given high risk perinatal transmission cdc recommends screening pregnant women hbv first prenatal safe nonimmune pregnant women receive hbv based limited available evidence american association study liver diseases aasld recommends antiviral therapy pregnant women whose viral load exceeds growing body evidence shows antiviral therapy initiated third trimester significantly reduces transmission systematic review antiretroviral pregnancy registry database found increased risk congenital anomalies tenofovir reason along potency low risk resistance aasld recommends systematic review metaanalysis found lamivudine initiated early third trimester also significantly reduced mothertochild transmission hbv without known adverse acog states evidence available suggest particular mode delivery ie vaginal vs cesarean better reducing vertical transmission mothers cdc recommend neonates born mothers hbv receive hepatitis b immune globulin hbig well hbv vaccine within hours infants received hbig hbv vaccine breastfeeding estimates rate hcv vertical transmission range systematic review metaanalysis found risk hcvpositive hivnegative study found risk vertical transmission hcvpositive hivpositive studies found risk vertical transmission high among hivpositive risk vertical transmission higher virus detectable mothers evidence indicate mode delivery ie vaginal vs cesarean effect vertical women hcvpositive hivnegative breastfeeding safe cdc guidelines suggest avoiding womans nipples cracked bleeding reduce risk pregnant women contract hev significant risk developing fulminant hepatitis maternal mortality rates high commonly third trimester systematic review metaanalysis studies included people found maternal casefatality rates cfr fetal cfr among women developed fulminant hepatic failure cfr httpsenwikipediaorgwikihepatitis